Woodline Partners LP Boosts Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Woodline Partners LP lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 19.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 540,192 shares of the biotechnology company's stock after purchasing an additional 86,614 shares during the period. Woodline Partners LP owned 0.85% of Blueprint Medicines worth $47,116,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. R Squared Ltd bought a new stake in Blueprint Medicines during the 4th quarter valued at $51,000. Headlands Technologies LLC bought a new stake in shares of Blueprint Medicines in the fourth quarter valued at about $65,000. Thematics Asset Management purchased a new stake in Blueprint Medicines in the fourth quarter worth about $72,000. Covestor Ltd lifted its stake in Blueprint Medicines by 62.7% in the fourth quarter. Covestor Ltd now owns 973 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 375 shares during the period. Finally, Asset Management One Co. Ltd. bought a new position in Blueprint Medicines during the 4th quarter worth about $88,000.

Insider Transactions at Blueprint Medicines

In other news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now directly owns 69,266 shares in the company, valued at approximately $6,581,655.32. The trade was a 3.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the sale, the insider now owns 18,270 shares of the company's stock, valued at $1,692,167.40. The trade was a 14.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,777 shares of company stock worth $1,256,490. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Stock Down 1.2%

NASDAQ BPMC traded down $1.17 during trading on Thursday, hitting $100.34. The company's stock had a trading volume of 487,838 shares, compared to its average volume of 780,682. Blueprint Medicines Co. has a fifty-two week low of $73.04 and a fifty-two week high of $121.90. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The company has a market cap of $6.48 billion, a PE ratio of -92.91 and a beta of 0.83. The business's 50 day simple moving average is $90.53 and its 200-day simple moving average is $94.63.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The company had revenue of $149.41 million for the quarter, compared to analysts' expectations of $158.31 million. During the same period in the prior year, the firm posted $1.40 EPS. The firm's revenue for the quarter was up 55.5% on a year-over-year basis. On average, equities analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BPMC. Wolfe Research began coverage on shares of Blueprint Medicines in a research report on Tuesday, March 18th. They issued an "outperform" rating for the company. JMP Securities reissued a "market outperform" rating and issued a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Wedbush reaffirmed an "outperform" rating and set a $128.00 target price on shares of Blueprint Medicines in a research report on Thursday, May 1st. HC Wainwright reiterated a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Friday, May 2nd. Finally, Morgan Stanley started coverage on Blueprint Medicines in a research report on Thursday, March 20th. They issued an "equal weight" rating and a $100.00 price target for the company. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Blueprint Medicines presently has a consensus rating of "Moderate Buy" and an average price target of $126.56.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.